Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymoma

26 Mar 2025

Abstract excerpt

Spinal ependymoma and myxopapillary ependymoma are the two most common spinal ependymal tumor types that feature distinct histological characteristics, genetic alterations and DNA methylation profiles. Their histological distinction may be difficult in individual cases and molecular diagnostic assessment, in particular DNA methylome profiling, may then be required to assign the correct diagnosis. Expression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cancer-related molecular mechanisms research
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40137996
DOI: 10.1007/s00401-025-02866-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymomaPMID 40137996Read ↗

Strong nuclear expression of HOXB13 is a reliable surrogate marker for DNA methylome profiling to distinguish myxopapillary ependymoma from spinal ependymomaSemantic proximity Read ↗

Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.Semantic proximity Read ↗

High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymomaSemantic proximity Read ↗

The Molecular Feature of HOX Gene Family in the Intramedullary Spinal TumorsSemantic proximity Read ↗

Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumorsSemantic proximity Read ↗

Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing diseaseSemantic proximity Read ↗

Spinal low-grade ependymal tumors harboring telomerase reverse transcriptase promoter mutation and chromosome 7 gain with methylation profile of spinal subependymoma.Semantic proximity Read ↗

Clinically aggressive pediatric spinal ependymoma with novel MYC amplification demonstrates molecular and histopathologic similarity to newly described MYCN-amplified spinal ependymomasSemantic proximity Read ↗

Morphology‐based molecular classification of spinal cord ependymomas using deep neural networksSemantic proximity Read ↗

Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imagingSemantic proximity Read ↗

Spinal Myxopapillary Ependymomas Demonstrate a Warburg PhenotypeSemantic proximity Read ↗

Molecular genetic alterations on chromosomes 11 and 22 in ependymomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.